Category Archives: Neuroscience

Neuroscience

Putting Brains on the Witness Stand – The Regulatory Review

Neuroscientific evidence in the courtroom may test judges and standards of admissibility.

As the United States continues to bear witness to high-profile episodes of police violence, many have wondered: What was that officer thinking?

Although it might seem as if we can never know for sure, neuroscience has already entered criminal courtrooms, with some lawyers extolling the disciplines ability to peer into the subconscious. According to its proponents, neuroscientific evidence has the potential to promote just outcomes by making it easier to determine whether someone is lying.

Skeptics argue that neuroscientific evidence presents a host of concerns, including privacy and due process rights. Many neuroscientists point to a more basic issue.

Despite advances in understanding the human brain, neuroscience has yet to decipher the workings of mind. Technologies exist that produce accurate inferences about what someone is thinking. But devices that can actually read intentions and memoriesdevices that could probe a violent police officers mindare still the stuff of science fiction. For now, it largely remains up to judges to regulate what kinds of neuroscientific evidence make it into court.

The most common kind of neuroscientific evidencesometimes called neurobiological evidenceis information about a defendants brain health and function. This information usually takes the form of brain scans, neuropsychological tests, or medical history records. A physician or other expert can testify that a particular scan, test, or record indicates that a defendant is physically unable to form the requisite intent for the charged offense or as mitigating evidence at sentencing.

The connection between neurobiological evidence and the ultimate issue of a defendants mental state raises difficult questions. For example, even though a brain scan may be able to show, with high accuracy, that a certain defendant has significant brain damage, does this mean that the defendant is legally insane? The answer may depend on the location and extent of the brain damage, but it will also depend on how the judge construes the definition of legal insanity. Can the legal concept of recklessness be matched with a specific pattern of brain activity? Should neuropsychological tests influence determinations of a teenagers culpability?

Forensic neuroscience may present even thornier questions. This variety of neuroscientific evidence derives from EEG-based technologies which measure specific brain signals associated with memory recognition to detectat least in theorywhether a suspect has hidden knowledge of a crime. After decades on the fringe of neuroscience, brain fingerprinting may be poised to attain mainstream status in the near future.

It is largely up to trial judges to untangle these questions about the proper role of neuroscience in the courtroom. In the United States, the Federal Rules of Evidence and their state law counterparts regulate kinds of information that lawyers can introduce at trial. Expert testimony, such as neuroscientific evidence, is further governed by standards derived from two U.S. Supreme Court cases: Daubert v. Merrell Dow Pharmaceuticals and Frye v. United States. Both standards serve as guidelines for weeding out unreliable scientific, technical, or otherwise specialized evidence.

The Daubert standard obliges judges to look at factors such as whether the method or theory used to generate the evidence has been tested, whether there is published peer-reviewed work about it, its error rate, whether there are any standards of operation, and whether it is generally accepted in the relevant field. Federal courts and many states use the Daubert standard.

Some states retain the older Frye standard, which simply requires judges to determine whether the method or theory is generally accepted in the relevant field. Of course, judges must also determine whether experts are qualified and whether their information is helpful to the trier of fact.

Many kinds of neurobiological evidencescans, tests, and medical recordshave a good chance of satisfying the Daubert test. They are well-validated, the subject of peer-reviewed work, tend to have low error rates, and have extensive and detailed standards of operation. Even brain fingerprinting may stand a chance; one U.S. court has already admitted it as evidence in a criminal case.

Yet Daubert, Frye, and related evidence rules have failed to catch faulty scientific evidence. In 2009, the National Academy of Sciences released a report calling for a reevaluation of commonly admitted forensic techniques, such as bite mark and fingerprint analyses. Despite widespread belief in their reliability, the Academy report indicated that few had solid scientific foundations. Indeed, over a hundred people convicted on the basis of these unreliable techniques have been exonerated.

Since the reports publication, various states and organizations have taken steps to remedy the use of bad science in criminal cases. Under Daubert and Frye, however, trial judges remain the final arbiters of what constitutes acceptable expert testimony. The Supreme Court has clarified that appellate courts should review decisions on the admissibility of expert testimony for abuse of discretiona low bar to clear.

Most neuroscientific evidence does rest on solid scientific foundations. And some studies have found that jurors, once thought to be easily swayed by the mere hint of science, may not find information about a defendants brain especially persuasive.

Since neurolaw is still an infant field, little empirical research exists on the potential limits and risks of putting brains on the witness stand for experts (and judges) to draw upon. Even if the science itself is not faulty, lawyers may call experts who overstate what that science can prove or frame a hotly debated opinion as the fields consensus.

These issues may not be unique to neuroscientific evidence. Toxic tort litigation, for example, is often a battle of the experts. Nevertheless, neuroscientific evidence carries distinctive risks. Being able to uncover that police officers memoriesor those of a robbery witness, or a teenage defendantcould be the difference between guilty and not guilty. That is a lot of stress to put on judges brains.

Here is the original post:
Putting Brains on the Witness Stand - The Regulatory Review

Neuroscience

Neuroscience research finds brain structure differences in men and women are not strongly linked to behavioral differences – PsyPost

Brain structure differences in men and women are only weakly linked to behavioral differences, according to new research that analyzed two large independent brain imaging datasets. The findings have been published in the journal Psychological Science.

The presence of sex differences in human behavior is well documented, but whether these behavioral differences are related to differences in male and female brain structure has been unclear. Previous research has indicated that sex differences in brain structure are, in fact, related to sex differences in behavior. But the new findings provide evidence that this relationship is mostly driven by brain size.

My background in neuropsychology and neuroimaging made me interested in this topic, i.e., whether sex differences in the brain are related to sex differences in behavior, explained study author Liza van Eijk, a psychology lecturer at James Cook University.

Sex differences have been found for behavior, for example, on average better visuospatial skills for males than females, and vice versa, on average better empathy skills found for females than males. Sex differences have also been found for disease and mental disorders, such as the higher prevalence for autism spectrum disorder in males vs. females, and vice versa, higher prevalence for depression in females vs. males.

In addition, several sex differences have been found in the brain, such as that male brains are on average 10-15% larger than female brains. The question that remained was whether sex differences in behavior could be related to sex differences in the brain, and if so, this relationship could provide insights for disorders that have shown sex differences.

The researchers used data from the Human Connectome Project and the Queensland Twin IMaging Study to examine individual differences in male and female brain structure. Both the Human Connectome Project and Queensland Twin IMaging Study used high-quality imaging technology to measure brain structure.

The studies also collected a variety of physical, neurocognitive, and behavioral data from participants, including but not limited to body mass index, intelligence, working memory performance, personality traits, and psychiatric symptoms. The combined sample included data from 2,153 adults.

To eliminate societal and cultural factors that could influence sex differences in behavior, van Eijk and her colleagues examined brain differences among individuals of the same-sex. In other words, they separately compared women to other women and compared men to other men.

Considering that women and men are subject to differential societal and cultural norms, we examined individual differences in brain structure along a male-female dimension, separately for each sex, van Eijk told PsyPost.

Depending on differences in genetic predispositions as well as exposure and sensitivity to sex hormones, some men will develop a more female-like brain whereas other men will develop a more male-like brain, and vice versa for women. Next, we also examined behavioral differences (such as personality and cognition) along a male-female dimension. Then, we looked at whether these brain and behavioral differences along a male-female dimension were related to one another.

The researchers found a statistically significant association between brain differences and behavioral differences, but the association disappeared after accounting for differences in brain size.

We (only) found a weak relationship between brain and behavioral sex differences, showing that brain structure differences in men and women are not strongly linked to behavioral differences and that likely many other factors play a role in behavioral sex differences, van Eijk explained. In addition, the weak relationship was mostly explained by differences in brain size, suggesting that future research examining the link between brain and behavior needs to carefully consider differences in brain size.

The study included a number of strengths, including its relatively large sample size. But, as with all research, the findings include a few caveats.

This is a correlational study, so therefore we cannot conclude anything about the direction of the effect, van Eijk told PsyPost. Further research is needed to determine whether sex (but also gender) differences in brain and behavior are the result of a common factor (e.g. masculinization of the brain early during gestation) and/or whether sex differences in the brain influence behavior, and/or vice versa, how these differences in behavior influence the brain.

In addition, it is unclear whether this relationship between sex differences in brain and behavior changes across the lifespan, in particular of interest are periods such as puberty and menopause, periods characterized by significant changes in sex hormone levels.

I believe it is important not to ignore sex differences in research, no matter how small, as examining these could provide new clues for behavior and disease showing sex differences in their prevalence or symptom expression, van Eijk added. However, it is important to acknowledge that individual differences are often larger than the sex differences observed and that sex differences found (whether in brain or behavior) do not provide any evidence for which sex is most superior.

The study, Are Sex Differences in Human Brain Structure Associated With Sex Differences in Behavior?, was authored by Liza van Eijk, Dajiang Zhu, Baptiste Couvy-Duchesne, Lachlan T. Strike, Anthony J. Lee, Narelle K. Hansell, Paul M. Thompson, Greig I. de Zubicaray, Katie L. McMahon, Margaret J. Wright, and Brendan P. Zietsch.

Read more:
Neuroscience research finds brain structure differences in men and women are not strongly linked to behavioral differences - PsyPost

Neuroscience

How does the brain create our perception of reality? – EurekAlert

WASHINGTON, D.C. New findings from studies in both people and animals are revealing clues about how sensory information and cognitive processes interact in the brain to produce our perception of the world. The findings were presented at Neuroscience 2021, the annual meeting of the Society for Neuroscience and the worlds largest source of emerging news about brain science and health.

Sensory inputs, such as sights, sounds, and touches, yield rich information about the external world. But our perception and interpretation of sensations are heavily shaped by cognitive processes such as attention, expectation, and memory. A better understanding of the neural basis of perceptual phenomena will help clarify both ordinary experiences such as the ability to pick a single voice out of a noisy background and disorders in which perception is altered such as attention-deficit/hyperactivity disorder, autism, schizophrenia, and Alzheimers disease.

Todays new findings show:

The neuroscience findings presented today demonstrate the importance of comparative brain studies in long-standing issues in human perception and cognition, said Sabine Kastner, a professor at Princeton University who studies visual perception and attention. These advances show how research in different model systems can come together to inform our understanding of the human brain, from the neurobiological mechanisms of perception to our subjective perceptual experiences.

This research was supported by national funding agencies including the National Institutes of Health and private funding organizations. Find out more about sensory perception and the brain on BrainFacts.org.

Mechanisms of Perception Press Conference Summary

PV Neurons Enhance Cortical Coding in the Cocktail Party Problem

Kamal Sen, kamalsen@bu.edu, Abstract P442.10

Body Ownership and the Neural Processes of Memory Encoding and Reinstatement

Heather Iriye, heather.iriye@ki.se, Abstract P505.02

The Neural Bases of Simulation in the Primate Brain

David Sheinberg, David_Sheinberg@brown.edu, Abstract P775.01

Closed-loop EEG-TMS Modulation of Frontal-occipital Communication Enhances Visual Perception

Nitzan Censor, censornitzan@tauex.tau.ac.il, Abstract P767.09

###

About the Society for Neuroscience

The Society for Neuroscience is the world's largest organization of scientists and physicians devoted to understanding the brain and nervous system. The nonprofit organization, founded in 1969, now has nearly 37,000 members in more than 90 countries and over 130 chapters worldwide.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Go here to see the original:
How does the brain create our perception of reality? - EurekAlert

Neuroscience

Harvard Neuroscientists Explore the Science of Acupuncture – SciTechDaily

Researchers have discovered neurons needed for acupunctures anti-inflammatory response,

Acupuncture is a traditional Chinese technique that has been used for millennia to treat chronic pain and other health problems associated with inflammation, yet the scientific basis of the technique remains poorly understood.

Now, a team of researchers led by neuroscientists at Harvard Medical School has elucidated the underlying neuroanatomy of acupuncture that activates a specific signaling pathway.

In a study conducted in mice and published October 13, 2021, in Nature, the team identified a subset of neurons that must be present for acupuncture to trigger an anti-inflammatory response via this signaling pathway.

The scientists determined that these neurons occur only in a specific area of the hindlimb regionthus explaining why acupuncture in the hindlimb works, while acupuncture in the abdomen does not.

This study touches on one of the most fundamental questions in the acupuncture field: What is the neuroanatomical basis for body region, or acupoint, selectivity? said lead investigator Qiufu Ma, HMS professor of neurobiology at Dana-Farber Cancer Institute.

One area of particular interest to the research team is the so-called cytokine stormthe rapid release of large quantities of cytokines that frequently drives severe, systemic inflammation, and can be triggered by many things, including COVID-19, cancer treatment, or sepsis.

This exuberant immune response is a major medical problem with a very high fatality rate of 15 percent to 30 percent, Ma said. Even so, drugs to treat cytokine storm are lacking.

In recent decades, acupuncture has been increasingly embraced in Western medicine as a potential treatment for inflammation.

In this technique, acupoints on the bodys surface are mechanically stimulated, triggering nerve signaling that affects the function of other parts of the body, including organs.

In a 2014 study, researchers reported that electroacupuncture, a modern version of traditional acupuncture that uses electrical stimulation, could reduce cytokine storm in mice by activating the vagal-adrenal axisa pathway wherein the vagus nerve signals the adrenal glands to release dopamine.

In a study published in 2020, Ma and his team discovered that this electroacupuncture effect was region specific: It was effective when given in the hindlimb region, but did not have an effect when administered in the abdominal region. The team hypothesized that there may be sensory neurons unique to the hindlimb region responsible for this difference in response.

In their new study, the researchers conducted a series of experiments in mice to investigate this hypothesis. First, they identified a small subset of sensory neurons marked by expression of the PROKR2Cre receptor. They determined that these neurons were three to four times more numerous in the deep fascia tissue of the hindlimb than in the fascia of the abdomen.

Then the team created mice that were missing these sensory neurons. They found that electroacupuncture in the hindlimb did not activate the vagal-adrenal axis in these mice. In another experiment, the team used light-based stimulation to directly target these sensory neurons in the deep fascia of the hindlimb.

This stimulation activated the vagal-adrenal axis in a manner similar to electroacupuncture. Basically, the activation of these neurons is both necessary and sufficient to activate this vagal-adrenal axis, Ma said.

In a final experiment, the scientists explored the distribution of the neurons in the hindlimb. They discovered that there are considerably more neurons in the anterior muscles of the hindlimb than in the posterior muscles, resulting in a stronger response to electroacupuncture in the anterior region.

Based on this nerve fiber distribution, we can almost precisely predict where electrical stimulation will be effective and where it will not be effective, Ma explained.

Together, these results provide the first concrete, neuroanatomic explanation for acupoint selectivity and specificity, Ma added. They tell us the acupuncture parameters, so where to go, how deep to go, how strong the intensity should be.

He noted that while the study was done in mice, the basic organization of neurons is likely evolutionarily conserved across mammals, including humans.

However, an important next step will be clinical testing of electroacupuncture in humans with inflammation caused by real-world infections such as COVID-19. Ma is also interested in exploring other signaling pathways that could be stimulated by acupuncture to treat conditions that cause excessive inflammation.

We have a lot of tough chronic diseases that still need better treatments, he said, such as inflammatory bowel syndrome and arthritis. Another area of need, he added, is excessive immune reactions that can be a side effect of cancer immunotherapy.

Ma hopes that his research will ultimately advance scientific understanding of acupuncture and provide practical information that can be used to improve and refine the technique.

Reference: A neuroanatomical basis for electroacupuncture to drive the vagaladrenal axis by Shenbin Liu, Zhifu Wang, Yangshuai Su, Lu Qi, Wei Yang, Mingzhou Fu, Xianghong Jing, Yanqing Wang and Qiufu Ma, 13 October 2021, Nature.DOI: 10.1038/s41586-021-04001-4

The work was primarily supported by the National Institutes of Health (grant R01AT010629), and partially supported by Harvard/MIT Joint Research Grants Program in Basic Neuroscience and the Wellcome Trust (grant 200183/Z/15/Z). For further information on salary support for the researchers, please refer to the paper.

Read more:
Harvard Neuroscientists Explore the Science of Acupuncture - SciTechDaily

Neuroscience

Whats the connection between migraine headaches and military service? – Norton Healthcare

Jeremy Jackson has served five tours of duty in Iraq and Afghanistan. Over the years Jeremy has survived mortar blasts, roadside bomb attacks and a Humvee rollover. Now posted to Fort Knox, Kentucky, as an operations supervisor, Jeremy is one of many whose military service appears connected to headaches and migraine.

The Department of Veterans Affairs reports that veterans are more likely to experience migraine and headaches than non-veterans. Nearly a third of veterans who served a one-year deployment to Iraq were diagnosed with migraine or showed signs of the condition.

Jeremy started developing migraine after a roadside bomb attack in 2008. The issue got progressively worse, and by 2011, he experienced several migraine attacks per month.

Now, I average anywhere from one to three migraine [episodes] a week, and I have headaches every single day, he said. The only thing I can do is go lie down. When the migraine really kicks in, theres a tendency of getting cold sweats, the throbbing and all that in your head, and then it makes you nauseous, and then I start throwing up.

Brian M. Plato, D.O., headache neurologist with Norton Neuroscience Institute, is seeing more and more service members in the Norton Neuroscience Institute Headache Center.

We have a lot of veterans who are referred into our practice, and they all have very different, but similar stories, Dr. Plato said. Many had exposures to a direct head injury, or many of them are around a lot of blasts. I think a lot of people dont understand the consequences of being near a blast.

Many dont recognize that their brain was affected, so it can be months or years before they get treatment, according to Dr. Plato.

Our providers of migraine and headache care are now available with Norton Telehealth and shorter wait times for appointments.

Call (502) 899-6782

Over the past several years, new migraine medications have become available. Preventive treatments for migraine can include oral medications, monthly injections and Botox, which is done every three months. There also are medications that can ease the symptoms once a migraine strikes.

Jeremy, who also has been diagnosed with an acquired brain injury, takes medication and receives Botox for his migraine symptoms. The treatment helps, but the condition is still an issue for him.

With the Botox, I probably have one migraine a week instead of three or four, he said.

While the medication doesnt always stop a migraine once it starts, it often will prevent the nausea and vomiting.

Even with medications and current treatments, theres still no cure for migraine. But Dr. Plato is optimistic, as interest in the condition is growing.

I wish that I could say that there was some revolutionary treatment that was just around the corner, but that wouldnt be true, he said. Treatments that have been developed over the past several years are making researchers recognize that this is a condition with a high level of disability that affects many people. And so I think that youre going to see significant progress on this over the next five to 10 years.

For Jeremy and his fellow service members who experience migraine attacks, that progress cant come soon enough.

Fighting overseas, I never thought I would end up with an enemy in my own head, he said. And I know many others in the same boat. We just want it to get better.

Continued here:
Whats the connection between migraine headaches and military service? - Norton Healthcare

Neuroscience

Understanding the brain: Why we sleep, dream, and remember – Iowa Now

While packing boxes to move to Iowa City in 2017, Ted Abel found a paper from his high school AP biology course. On it was a comment from his teacher saying they hoped he would maintain his interest inneurophysiology.

It reminded the University of Iowas Roy J. Carver Chair in Neuroscience just how long ago he became interested in the mysteries of thebrain.

It was very early on that I became interested in neuroscience, says Abel. Its astounding that no matter how complex it is, the brain gives rise to Jackson Pollock paintings, to novels, andphilosophy.

A native of the Philadelphia area, Abel applied to Swarthmore College at 16. He said his desired profession was neurochemist, but since there was no neuroscience course or major then, Abel didnt take a direct route into thefield.

I got interested in chemistry and physics first. It was that side of science and the ability to understand nature in quantitative terms that fascinated me, saysAbel.

A livestream of the lecture will be available here.

Abel graduated from Swarthmore College with a degree in chemistry in 1985. He continued his education at Cambridge and completed his PhD at Harvard, learning from several world-renowned scientists on theway.

I am thankful for my education and especially my mentors, says Abel. I was a Marshall scholar in Cambridge with Tim Hunt, learning some early molecular biology, and then in my PhD I worked with Tom Maniatis, who is considered the father of molecular biology. I was able to bring these molecular approaches into neuroscience as a postdoc when I worked with Eric Kandel at Columbia University. Both Tim Hunt and Eric Kandel went on to win the Nobel Prize in the early2000s.

It wasnt until later in his education that he began to ponder larger, more philosophical questions about the brain. Why do we sleep? Why do we dream? How do weremember?

Abel brought those questions with him to the University of Pennsylvania in 1998, where he began working as an assistant professor, eventually running one of the countrys oldest neuroscienceprograms.

Abel found a unique opportunity to further his research on sleep and memory in Iowa City, where he moved in 2018, as founding director of the Iowa NeuroscienceInstitute.

We have a university that has a century-old tradition of neuroscience research, education, and clinical care, says Abel. Former UI Dean Carl Seashore was one of the few people at a meeting for Freuds only visit to the United States. Its an extraordinarily collaborative neuroscience community at the University of Iowa, ranging from psychology to pharmacology topsychiatry.

When Abel presents the UIs 38th Presidential Lecture on Nov. 7, he will discuss research that is more than two decades in themaking.

One of the things Im trying to get across is the way in which our knowledge of memory and of sleep enables us to answer questions that philosophers have asked for centuries, Abelsays.

Abel, professor and chair of the Department of Neuroscience and Pharmacology in the UI Roy J. and Lucille A. Carver College of Medicine and director of the Iowa Neuroscience Institute, will deliver a lecture titled Its not a dream, its a memory, at 3:30 p.m. Sunday, Nov. 7, in the Iowa Memorial Union MainLounge.

Why is sleep and the brain an important topic to discuss in yourlecture?

Whats interesting is that there still is a view that sleep is for the weak and if you just suck it up, you can get through it. The thing weve found is that youcant.

I will talk about some experiments in mice where we are able to manipulate molecules in the brain to make them resistant to sleep deprivation. Normally sleep loss would impair memory, but if we rewire the brain, we can train animals, sleep deprive them, and their memory is notimpaired.

The other thing people dont realize is that the impact of staying awake all night is not just that youre going to have trouble the next day. Its that as youre sleep deprived, your body has metabolic, cognitive, and immunechallenges.

What challenges are still ahead in understanding the role of sleep andmemory?

The real challenge we have is translational researchgoing from the bench to the bedside. We have done really well from the bedside to the bench. If we have a patient that has an alteration in a particular gene or a problem in an area, we can model it at the bench, but coming back to treatments has been moredifficult.

One of the reasons that is an issue with neurological, psychiatric, and neurodevelopmental conditions is that they occur across the lifespan and we dont have a marker or a sign that signals future conditions or complications. We have made dramatic improvements in our treatment of heart disease, for example. That is not necessarily because we can better measure plaque in arteries; its because we know that hypertension 10 years before is a marker of developing heartdisease.

In the brain, we dont have those measures that signal future conditions. However, sleep may be one of those measures to help us identify neurological, psychiatric, and neurodevelopmental conditions in thebrain.

How have humans sleep habits changed over time, and how does this change the way sleep isstudied?

When you look at the 1950s to now, we are sleeping about 1.2 hours less a day now, and the pandemic, with all the related stress, has made that worse. We are way below what health experts say we need. It varies across life and for each person because sleep is not a single phenomenon. In humans, when we first go to sleep at night, we go into non-REM sleep. Thats a deep sleep, and later in the night you have REM sleep, and that is a lighter sleep. We can more easily be woken up from REM sleep. If you always get up early, you are going to lose your REM sleep. You may think you are getting enough sleep, but you might be missing a part and not completing the types of sleep youneed.

What do you hope to convey in your lecture? What do you hope people take away fromit?

Our knowledge of memory and sleep, while built upon the technical advances driven by investments like the Iowa Neuroscience Institute and the BRAIN Initiative, enables us to answer age-old questions that have been with humanity from the beginning: Why do we sleep? Why do we dream? And how do we remember? My lecture will seek to answer some of thosequestions.

What does it mean to you to have been chosen to deliver the presidentiallecture?

Its a tremendous honor. Its a chance to speak to the broad communitystudents, faculty, staff, and also the Iowa City communityand talk generally about the impact that neuroscience has had on our understanding of the brain. Its also a chance to describe the tremendous impact that the Iowa Neuroscience Institute has had on the community since its founding five yearsago.

See original here:
Understanding the brain: Why we sleep, dream, and remember - Iowa Now

Neuroscience

The Neuro Impact Factor – How just a glance at OOH can have a lasting impact – AdNews

The outdoor industry,as restrictions ease and foot traffic increases, is preparing to improve the connectionbetween advertisers and audiences, and provide metrics for measuring impact.

The Neuro Impact Factor, a world first, coming out of the Outdoor Media Associations (OMA) neuroscience study in partnership with Neuro-Insight, will be launched to market in January.

The OMA will be holding its firstOUT-FRONT event on Tuesday, November 9, to talk more about the Neuro Impact Factor and other innovations to be launched in 2022.

The research, using the largest media neuroscience study of its kind, used eye-tracking and brain-imaging technology to provide over one million points of data on how out-of-home (OOH) signs impact the subconscious.

By measuring peak moments in long term memory encoding and emotional intensity in the brain, Neuro-Insight was able to evaluate the effect of an outdoor sign at just a glance.

More than 2,000 people took part in the study and their responses to more than 800 classic and digital signs were recorded and analysed.

Campaigns seen on classic signs fall within the range of memory encoding, similar to a 30 second radio commercial or a 15 second television spot.Adding a digital aspect to an outdoor campaignwill mke it 63% more impactful.

"What we have accomplished in doing this research is going beyond the how many part of the equation that comprises mature media measurement," says Peter Pynta, CEO at Neuro-Insight.

"With the Neuro Impact Factor, we have brought in a quality dimension in a scalable way. We finally have three parts of the triangle of reach, frequency and now impact."

Armed with the Neuro Impact Factors key metrics-- memory and emotion -- the outdoor industry can provide new insights alongside the best-in-class audience measurement found in MOVE, to help agencies and advertisers make scientifically informed decisions when planning their OOH campaigns.

"This research is a game-changer for out-of-home. Not only have we provided undeniable, scientific proof of the subconscious impact of advertising, but we have also shown that just one glance at one of our signs is sufficient for brand messages to elicit an emotional response that encodes into long term memory," saysCharmaine Moldrich, OMA CEO.

"Whats more, it introduces a qualitative measure that will be added in January 2022 to our audience measurement system, MOVE, giving agencies and clients yet another tool to help them plan and buy their out-of-home campaigns."

The findings of the study were launched in September via a virtual event hosted by OMA CEO Charmaine Moldrich and featuring guest speakers Neuro-Insight CEO, Peter Pynta, neuroscience academic Professor Joel Pearson and followed by a Q&A with MOVE 2.0 Lead, Grant Guesdon, Managing Partner of Avenue C and Outdoor Futures Council Chair Pia Coyle, and Head of Out of Home at Dentsu, Emma Hegg.

"This is another step toward attribution and understanding the value of out-of-home," says Moldrich.

"These results will inform the development of a new currency that advertisers and agencies can use alongside reach and frequency reports.

"The Factor will be exclusive to MOVE, and the first qualitative metric in the world to unite validated real-world effectiveness with the quantitative metrics available in the system."

Have something to say on this? Share your views in the comments section below. Or if you have a news story or tip-off, drop us a line at adnews@yaffa.com.au

Sign up to the AdNews newsletter, like us on Facebook or follow us on Twitter for breaking stories and campaigns throughout the day.

Read the rest here:
The Neuro Impact Factor - How just a glance at OOH can have a lasting impact - AdNews

Neuroscience

Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences – Yahoo Finance

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it will participate in four upcoming virtual investor conferences during the months of November and December.

Event:

Virtual Guggenheim 3rd Annual Neuro/Immunology Conference

Date:

November 15, 2021

Format:

One-on-one meetings with members of the investor relations team

Event:

Stifel 2021 Virtual Healthcare Conference

Date:

November 16, 2021

Format:

Fireside chat with Chairperson and CEO Tony Coles, M.D.

One-on-one meetings with members of the management team

Time:

8:40 a.m. ET

Event:

Jefferies London Healthcare Conference

Date:

November 18, 2021

Format:

One-on-one meetings with members of the management team

Event:

Evercore ISI HealthCONx Conference

Date:

December 1, 2021

Format:

Fireside chat with Chairperson and CEO Tony Coles, M.D.

One-on-one meetings with members of the management team

Time:

9:40 a.m. ET

Live audio webcasts of the virtual conference fireside chats can be accessed on the investor relations section of the Cerevel Therapeutics website here. Replays will also be available in the same section of the companys website.

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases with a targeted approach to neuroscience that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons, epilepsy, schizophrenia, and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit http://www.cerevel.com.

Story continues

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our upcoming virtual investor conference participation and the potential attributes and benefits of our product candidates. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading Risk Factors in our Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Kate ContrerasReal Chemistrykcontreras@realchemistry.com

Investor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com

See the original post here:
Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences - Yahoo Finance

Neuroscience

$1.7M MPower Grant to Support UMCP, UMB Health Research Collaborations – Maryland Today

A new grant will provide $1.725 million over three years to support research collaborations between the University of Maryland, College Park (UMCP) and the University of Maryland, Baltimore (UMB) aiming to improve health care.

The grant from the University of Maryland Strategic Partnership, MPowering the State, and accompanying cooperative agreement will allow researchers across the College Park campus to partner with UMBs Institute for Clinical and Translational Research (ICTR). The institute focuses on putting health-related scientific findings to work, and offers expert patient- and community-centered services; biostatistical support for study design, implementation, and interpretation; and pre- and postdoctoral training awards.

The MPower award will help researchers access resources for clinical training, reduce barriers to patient recruitment and open new avenues for human-subject research at UMCP.

The effort is co-led by Dr. Stephen N. Davis, the Dr. Theodore E. Woodward Chair of the Department of Medicine at the University of Maryland School of Medicine and director of the ICTR in Baltimore, and Professor Elizabeth Quinlan, the Clark Leadership Chair in Neuroscience, Department of Biology, and director of the Brain and Behavior Instituteat UMCP.

Access to ICTR resources will enable the translation of high-impact research from the laboratory to the clinic, said Quinlan. The MPower funding to establish this strategic partnership reflects the commitment to training and will accelerate new bi-campus collaborations.

The ICTR, supported by funding from the National Institutes of Health, was established at UMB in 2017 as a universitywide, interdisciplinary hub with a mission to turn basic research findings into novel technologies and practices with communitywide impact. Through the MPower funding, College Park faculty researchers in the life sciences, public health, neuroscience, bioengineering and other disciplines related to clinical and translational research are now eligible to submit proposals for services provided by the ICTR. In addition, College Park students, postdocs and faculty will be invited to compete for career development and mentoring funding. College Park faculty are also eligible to apply for the ICTR Accelerated Translational Incubator Pilot voucher program.

To further strengthen this partnership, MPower funds will continue to develop UMBs bioinformatic infrastructure, which applies computational analysis to biological and health information.

These resources will scale up the ICTRs informatics capabilities and help generate compelling data that demonstrate the effective and seamless clinical research partnership of the two campuses, said Davis. The MPower agreement will create a clinical research network across Maryland that benefits both the population of the state and faculty in Baltimore and College Park.

The MPower announcement follows the news earlier this year that the University of Maryland achieved its highest-ever ranking in the National Science Foundations Higher Education Research and Development survey, as a result of Baltimore and College Park research enterprise being linked together for the first time.

"This will create exciting new opportunities for our researchers to collaborate and deepen the impact of our combined research productivity across our College Park and Baltimore campuses," said Interim Vice President for Research Amitabh Varshney. "For College Park researchers new to the ICTR, the program will provide a high-quality environment for clinical and translational research and will foster innovation in research methods and training."

Read the original here:
$1.7M MPower Grant to Support UMCP, UMB Health Research Collaborations - Maryland Today

Neuroscience

Exicure to Present at Upcoming Scientific Conferences – Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced presentations at the following scientific conferences during the month of November:

TIDES EUTitle: "Development of Spherical Nucleic Acids Targeting SCN9A For the Treatment of Neuropathic Pain"Presented by: Bart Anderson, Senior Director, R&DDate: November 16, 2021Time: 8:45am CET / 1:45am U.S. CST

Neuroscience 2021 (The Society for Neuroscience)Poster 1: "Spherical Nucleic Acids Targeting FXN Induce Frataxin Expression in Models of Friedreichs Ataxia"Presented by: Grant Corbett, Group Lead, NeurosciencePoster 2: "Biodistribution of Spherical Nucleic Acids in the Mouse CNS Following ICV, ICM and IT Delivery"Presented by: Lauren Moore, Senior Scientist, NeuroscienceNovember 8-11, 2021

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN, a lipid-nanoparticle SNAbased therapeutic candidate, for the intrathecal treatment of Friedreichs ataxia (FA). Exicures therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA. http://www.exicuretx.com

See the article here:
Exicure to Present at Upcoming Scientific Conferences - Business Wire